FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220761491> ?p ?o ?g. }

• W4220761491 endingPage "892" @default.
• W4220761491 startingPage "882" @default.
• W4220761491 abstract "TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) is a co-inhibitory receptor of T-cell and natural killer cell activity. Targeting TIGIT with or without PD-1/PD-L1 checkpoint inhibition may enhance antitumor immunity.This Phase 1a/b trial was a first-in-human, open-label, multicenter, dose-escalation and -expansion study in patients with locally advanced or metastatic solid tumors. Using 3 + 3 design, patients underwent 14-day treatment cycles with anti-TIGIT antibody etigilimab alone (Phase 1a; 0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously) or in combination with anti-PD-1 antibody nivolumab (Phase 1b; 3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab). Primary objective was safety and tolerability.Thirty-three patients were enrolled (Phase 1a, n = 23; Phase 1b, n = 10). There were no dose-limiting toxicities (DLT). MTD for single and combination therapy was not determined; maximum administered dose was 20 mg/kg. The most commonly reported adverse events (AE) were rash (43.5%), nausea (34.8%), and fatigue (30.4%) in Phase 1a and decreased appetite (50.0%), nausea (50.0%), and rash (40%) in Phase 1b. Six patients experienced Grade ≥3 treatment-related AEs. In Phase 1a, 7 patients (30.0%) had stable disease. In Phase 1b, 1 patient had a partial response; 1 patient had prolonged stable disease of nearly 8 months. Median progression-free survival was 56.0 days (Phase 1a) and 57.5 days (Phase 1b). Biomarker correlative analyses demonstrated evidence of clear dose-dependent target engagement by etigilimab.Etigilimab had an acceptable safety profile with preliminary evidence of clinical benefit alone and in combination with nivolumab and warrants further investigation in clinical trials." @default.
• W4220761491 created "2022-04-03" @default.
• W4220761491 creator A5002429484 @default.
• W4220761491 creator A5005968330 @default.
• W4220761491 creator A5028472820 @default.
• W4220761491 creator A5029563022 @default.
• W4220761491 creator A5045993166 @default.
• W4220761491 creator A5061012285 @default.
• W4220761491 creator A5063550429 @default.
• W4220761491 creator A5072094247 @default.
• W4220761491 creator A5079842256 @default.
• W4220761491 creator A5086287522 @default.
• W4220761491 date "2022-03-01" @default.
• W4220761491 modified "2023-10-18" @default.
• W4220761491 title "A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors" @default.
• W4220761491 cites W1552754679 @default.
• W4220761491 cites W1965827638 @default.
• W4220761491 cites W1972338421 @default.
• W4220761491 cites W1981480494 @default.
• W4220761491 cites W1983812780 @default.
• W4220761491 cites W1987165863 @default.
• W4220761491 cites W1999689279 @default.
• W4220761491 cites W2019607817 @default.
• W4220761491 cites W2029399624 @default.
• W4220761491 cites W2049452608 @default.
• W4220761491 cites W2050457398 @default.
• W4220761491 cites W2072598572 @default.
• W4220761491 cites W2081484203 @default.
• W4220761491 cites W2099854994 @default.
• W4220761491 cites W2100158834 @default.
• W4220761491 cites W2142169541 @default.
• W4220761491 cites W2239788766 @default.
• W4220761491 cites W2403400382 @default.
• W4220761491 cites W2740980780 @default.
• W4220761491 cites W2753155927 @default.
• W4220761491 cites W2793629403 @default.
• W4220761491 cites W2808202038 @default.
• W4220761491 cites W2884495860 @default.
• W4220761491 cites W2885215095 @default.
• W4220761491 cites W2927046270 @default.
• W4220761491 cites W2940517335 @default.
• W4220761491 cites W2946033191 @default.
• W4220761491 cites W2958236287 @default.
• W4220761491 cites W3000210355 @default.
• W4220761491 cites W3006007810 @default.
• W4220761491 cites W3031115858 @default.
• W4220761491 cites W3037669104 @default.
• W4220761491 cites W3049330696 @default.
• W4220761491 cites W3084404519 @default.
• W4220761491 cites W3088018189 @default.
• W4220761491 cites W3088193078 @default.
• W4220761491 cites W3092274535 @default.
• W4220761491 cites W3102804765 @default.
• W4220761491 cites W3110073904 @default.
• W4220761491 cites W3134576549 @default.
• W4220761491 doi "https://doi.org/10.1158/1078-0432.ccr-21-2780" @default.
• W4220761491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34844977" @default.
• W4220761491 hasPublicationYear "2022" @default.
• W4220761491 type Work @default.
• W4220761491 citedByCount "19" @default.
• W4220761491 countsByYear W42207614912022 @default.
• W4220761491 countsByYear W42207614912023 @default.
• W4220761491 crossrefType "journal-article" @default.
• W4220761491 hasAuthorship W4220761491A5002429484 @default.
• W4220761491 hasAuthorship W4220761491A5005968330 @default.
• W4220761491 hasAuthorship W4220761491A5028472820 @default.
• W4220761491 hasAuthorship W4220761491A5029563022 @default.
• W4220761491 hasAuthorship W4220761491A5045993166 @default.
• W4220761491 hasAuthorship W4220761491A5061012285 @default.
• W4220761491 hasAuthorship W4220761491A5063550429 @default.
• W4220761491 hasAuthorship W4220761491A5072094247 @default.
• W4220761491 hasAuthorship W4220761491A5079842256 @default.
• W4220761491 hasAuthorship W4220761491A5086287522 @default.
• W4220761491 hasBestOaLocation W42207614911 @default.
• W4220761491 hasConcept C121608353 @default.
• W4220761491 hasConcept C126322002 @default.
• W4220761491 hasConcept C143998085 @default.
• W4220761491 hasConcept C159654299 @default.
• W4220761491 hasConcept C197934379 @default.
• W4220761491 hasConcept C203014093 @default.
• W4220761491 hasConcept C2777701055 @default.
• W4220761491 hasConcept C2778375690 @default.
• W4220761491 hasConcept C2778570526 @default.
• W4220761491 hasConcept C2779118045 @default.
• W4220761491 hasConcept C2780030458 @default.
• W4220761491 hasConcept C2780580376 @default.
• W4220761491 hasConcept C2780873365 @default.
• W4220761491 hasConcept C29730261 @default.
• W4220761491 hasConcept C31760486 @default.
• W4220761491 hasConcept C71924100 @default.
• W4220761491 hasConcept C90924648 @default.
• W4220761491 hasConceptScore W4220761491C121608353 @default.
• W4220761491 hasConceptScore W4220761491C126322002 @default.
• W4220761491 hasConceptScore W4220761491C143998085 @default.
• W4220761491 hasConceptScore W4220761491C159654299 @default.
• W4220761491 hasConceptScore W4220761491C197934379 @default.
• W4220761491 hasConceptScore W4220761491C203014093 @default.
• W4220761491 hasConceptScore W4220761491C2777701055 @default.

• next